Table 2. Clinical, anthropometric, and laboratory data of the participants with polycystic ovary syndrome with and without associated hepatic steatosis.
| PCOS and hepatic steatosis (n = 67) | PCOS without hepatic steatosis (n = 20) | P value a | |
|---|---|---|---|
| Age (years) | 35.0 ± 5.4 | 32.4 ± 6.4 | 0.07 |
| BMI (kg/m 2 ) | 35.7 ± 4.1 | 31.2 ± 5.2 | 0.001 |
| WC (cm) | 103 (88-128) | 95 (67-115) | < 0.001 |
| Obesity n (%) | 61 (91.0) | 14 (70.0) | 0.02 |
| Central obesity | 67 (100) | 18 (90) | 0.051 |
| Hyperandrogenism – n (%) | 53 (79.1) | 13 (65.0) | 0.13 |
| Hypertension – n (%) | 18 (26.9) | 4 (20.0) | 0.53 |
| Metabolic syndrome – n (%) | 39 (58.2) | 4 (20.0) | 0.007 |
| IR (HOMA-IR ≥ 2.7) – n (%) | 34 (50.7) | 7 (35.0) | 1.0 |
| IR (LAP ≥ 34.5) – n (%) | 61 (91.0) | 11 (55.0) | 0.001 |
| IR (VAI ≥ 1.675) – n (%) | 65 (97.0) | 17 (85.0) | 0.21 |
| DM – n (%) | 10 (14.9) | 1 (5.0) | 0.44 |
| FPG (mg/dL) | 89 (75-128) | 85 (68-98) | 0.06 |
| OGTT (mg/dL) | 123 (63-260) | 107 (56-155) | 0.005 |
| Glycohemoglobin (mg/dL) | 5.5 (4.9 - 6.9) | 5.4 (4.8-5.7) | 0.09 |
| IFG (%) | 12 (18.5) | 0 (0) | 0.06 |
| Dyslipidemia n (%) | 11(16.4) | 2 (10.0) | 0.72 |
| TG (mg/dL) | 140 (56-373) | 92 (49-173) | 0.003 |
| TC (mg/dL) | 195 (134 - 288) | 177 (127-228) | 0.01 |
| LDL (mg/dL) | 113 (59-203) | 112 (56 -165) | 0.17 |
| HDL (mg/dL) | 44 (23 - 77) | 47 (33- 59) | 0.48 |
| Insulin (µIU/mL) | 18 (8-55) | 15 (3-37) | 0.15 |
| ALT (U/L) | 36 (11-81) | 25 (13-37) | 0.001 |
| AST (U/L) | 24 (9-48) | 18 (11-31) | 0.001 |
| GGT (U/L) | 37 (14-234) | 29 (11-68) | 0.04 |
| ALT ≥ 69 U/L n (%) | 2 (2.9) | 0 (0) | 1.0 |
| AST ≥ 460 U/L n (%) | 2 (2.9) | 0 (0) | 1.0 |
| GGT ≥ 44 U/L n (%) | 23 (34.3) | 2 (10.0) | 0.32 |
| Phenotype A | 36 (53.7) | 9 (45.0) | 0.64 |
| Phenotype B | 6 (9.0) | 3 (15.0) | |
| Phenotype C | 11 (16.4) | 2 (10.0) | |
| Phenotype D | 14 (20.9) | 6 (30.0) |
PCOS: polycystic ovary syndrome; BMI: body mass index; WC: waist circumference; IR: insulin resistance; HOMA-IR: homeostasis model assessment of insulin resistance; LAP: lipid accumulation product; VAI: visceral adiposity index; FPG: fasting plasma glucose; DM: diabetes mellitus; OGTT: oral glucose tolerance test; IFG: impaired fasting glucose; TG: triglycerides; TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltransferase; phenotypes: A (hyperandrogenism [HA] + ovulatory dysfunction [OD] + polycystic ovary [PCOM]), B (HA + OD), C (HA + PCOM), D (OD + PCOM).